Ligand regulated protein-protein interaction system
A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner; wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 μM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.
1. A ligand regulated protein-protein interaction system comprising:
(a) a lipocalin-fold molecule;
(b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and
(c) a lipocalin-fold binding interaction partner;
wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and
wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand;
and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 μM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.
2. A ligand regulated protein-protein interaction system comprising:
(a) a lipocalin-fold molecule:
(b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and
(c) a lipocalin-fold binding interaction partner;
wherein the lipocalin-fold molecule has at least a first conformation when the lipocalin-fold ligand is not bound to the lipocalin-fold molecule and at least a second conformation when the lipocalin-fold ligand is bound to the lipocalin-fold molecule; and
wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand in the second conformation binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand in the first conformation;
and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 μM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.
3. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule is a molecule identical with a naturally occurring iLBP (intracellular lipid binding protein), a naturally occurring lipocalin or an anticalin, or is a derivative of any of these molecules with 1-30 amino acid exchanges and/or 1-50 amino acid deletions and/or 1-50 amino acid insertions.
4. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule is a derivative of a naturally occurring lipocalin or iLBP with at least one, two, three, four, five, six, seven, eight, nine, ten, 25 or 30 amino acid exchanges.
5. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule is a derivative of a naturally occurring lipocalin or iLBP with up to 50 amino acid deletions and/or up to 50 amino acid insertions outside of the structurally conserved β-barrel structure.
6. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule is a derivative of a naturally occurring lipocalin or iLBP with at least 70%, sequence identity in the β-barrel structure.
7. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule is a fragment of a naturally occurring lipocalin or a derivative thereof with a length of at least 80 amino acids covering at least the structurally conserved β-barrel structure of the lipocalin-fold, or wherein the lipocalin-fold molecule is a fragment of a naturally occurring iLBP or a derivative thereof with a length of at least 80, amino acids covering at least the structurally conserved β-barrel structure of the lipocalin-fold.
8. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 20-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand.
9. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 100-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand.
10. The ligand regulated protein-protein interaction system according claim 1 , wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 1000-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand.
11. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold ligand has a molecular weight of 1500 to 75 Da.
12. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold binding interaction partner is the lipocalin-fold molecule or the lipocalin-fold binding interaction partner comprises an antigen, a cell surface receptor, an antibody, an antibody fragment, or a non-antibody based scaffold, an affibody, a lipocalin-fold molecule, an iLPB, a LCN, an anticalin, an avimer, a DARPin, a fynomer, a Kunitz domain, a knottin, a monobody, a Sso7d-based binder, reduced charge Sso7d (rcSso7d)-based binder or Sac7d-based binder.
13. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule comprises an antigen, a cell surface receptor, an antibody, an antibody fragment, or a non-antibody based scaffold, an affibody, an iLPB, a LCN, an anticalin, an avimer, a DARPin, a fynomer, a Kunitz domain, a knottin, a monobody, a Sso7d-based binder, reduced charge Sso7d (rcSso7d)-based binder or Sac7d-based binder.
14. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold ligand has an affinity to the lipocalin-fold molecule of below 1 mM.
15. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold ligand is selected from the group consisting of fenretinide (15-[(4- hydroxyphenyl)amino]retinal), N-Ethylretinamide (PubChem CID: 5288173), all-trans retinoic acid (PubChem CID: 444795), axerophthene (PubChem CID: 5287722), A1120 (PubChem CID: 25138295) and derivatives thereof, 1,4 -butanediol (Pubchem CID: 8064), sphingosine-1-phosphate (Pubchem CID: 5283560), tetradecanoic acid (Pubchem CID: 11005), indicaxanthin (Pubchem CID: 6096870 and 12310796), violaxanthin I (Pubchem CID: 5281217), Montelukast (Pubchem CID: 5281040), Cyclandelate (Pubchem CID: 2893), Oxolamine (Pubchem CID: 13738), Mazaticol (Pubchem CID: 4019), Butoctamid (Pubchem CID: 65780), Tonabersat (Pubchem CID: 6918324), Novazin (Pubchem CID: 65734), Diphenidol (Pubchem CID: 3055), Neobornyval, Erlotinib (Pubchem CID: 92131336), Tanespimycin (Pubchem CID: 6505803), LMI070 (Pubchem CID: 85471316), Alloclamide (Pubchem CID: 71837), Diacetolol (Pubchem CID: 50894), Acotiamide (Pubchem CID: 5282338), Acoziborole (Pubchem CID: 44178354), Acumapimod (Pubchem CID: 11338127), Apalutamide (Pubchem CID: 24872560), ASP3026 (Pubchem CID: 25134326), AZD1480 (Pubchem CID: 16659841), BIIB021 (Pubchem CID: 16736529), Branaplam (Pubchem CID: 89971189), Brequinar (Pubchem CID: 57030), Chlorproguanil (Pubchem CID: 9571037), Clindamycin (Pubchem CID: 446598), Emricasan (Pubchem CID: 12000240), Enasidenib (Pubchem CID: 89683805), Enolicam (Pubchem CID: 54679203), Flurazepam (Pubchem CID: 3393), ILX-295501 (Pubchem CID: 127737), Indibulin (Pubchem CID: 2929), Metoclopramide (Pubchem CID: 12598248), Mevastatin (Pubchem CID: 64715), MGGBYMDAPCCKCT- UHFFFAOYSA-N (Pubchem CID: 25134326 having the structure 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine), MK0686 (Pubchem CID: 16102897), Navarixin (Pubchem CID: 71587743), Nefazodone hydrochloride (Pubchem CID: 54911), Pantoprazole (Pubchem CID: 4679), Pavinetant (Pubchem CID: 23649245), Proxazole (Pubchem CID: 8590), Siccanin (Pubchem CID: 71902), Sulfaguanole (Pubchem CID: 9571041), Sunitinib (Pubchem CID: 5329102), Suvorexant (Pubchem CID: 24965990), Tiapride (Pubchem CID: 5467), Tonabersat (Pubchem CID: 6918324), VNBRGSXVFBY QNN-UHFFFAOYSA-N (Pubchem CID: 24794418 having the structure N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide), YUHNXUAATAMVKD-PZJWPPBQSA-N (Pubchem CID: 44548240 having the structure [(1R)-2-[(3S)-3-[[5-chloro-2-(tetrazol-1-yl) phenyl]methylcarbamoyl]-3,4-dihydropyrazol-2-yl]-1-(4-fluorophenyl)-2-oxoethyl] propanoate), Ulimorelin (Pubchem CID: 11526696), Xipamide (Pubchem CID: 26618), Tropesin (Pubchem CID: 47530), Triclabendazole (Pubchem CID: 50248), Triclabendazole sulfoxide (Pubchem CID: 127657), Triclabendazole sulfone (Pubchem CID: 10340439) and Trametinib (Pubchem CID: 11707110).
16. The ligand regulated protein-protein interaction system according to claim 1 , wherein the lipocalin-fold molecule and the lipocalin-fold binding interaction partner are polypeptides.
17. A nucleic acid molecule comprising nucleotide sequences encoding the lipocalin-fold molecule and/or the lipocalin-fold binding interaction partner according to claim 1 , wherein the nucleic acid is selected from DNA or RNA.
18. A kit of at least two nucleic acid molecules, wherein the first nucleic acid molecule comprises nucleotide sequences encoding the lipocalin-fold molecule according to claim 16 , and wherein the second nucleic acid molecule comprises sequences encoding the lipocalin-fold binding interaction partner according to claim 16 , wherein the nucleic acids are preferably selected from DNA or RNA, in vitro transcribed RNA, RNA packaged in a retrovirus and RNA packaged in a lentivirus.
19. A vector comprising the nucleic acid molecule according to claim 17 .
20. A kit of at least two vectors comprising nucleic acid molecules according to claim 18 , wherein the first vector comprises a nucleic acid molecule encoding the lipocalin-fold molecule, and wherein the second vector comprises a nucleic acid molecule encoding the lipocalin-fold binding interaction partner.
21. A cell modified in vitro or eX vivo with a nucleic acid molecule, or with a vector or a kit of vectors to produce the lipocalin-fold molecule and/or the lipocalin-fold binding interaction partner according to claim 1 , or a kit comprising two or more of said modified cells.
22. A pharmaceutical preparation comprising a nucleic acid molecule according to claim 17 , and/or a vector or a kit of vectors, and/or a cell or a kit of cells.
23. A method of making a cell according to claim 21 , the method comprising introducing into the cell and/or stably integrating into the genome of the cell, in vitro or eX vivo a nucleic acid molecule or a kit of nucleic acid molecules, or a vector or a kit of vectors.
24. A non-human animal comprising the cell according to claim 21 .
25. A plant comprising the cell according to claim 21 .